ECSP088081A - Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente - Google Patents

Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Info

Publication number
ECSP088081A
ECSP088081A EC2008008081A ECSP088081A ECSP088081A EC SP088081 A ECSP088081 A EC SP088081A EC 2008008081 A EC2008008081 A EC 2008008081A EC SP088081 A ECSP088081 A EC SP088081A EC SP088081 A ECSP088081 A EC SP088081A
Authority
EC
Ecuador
Prior art keywords
therapeutic antibody
detection
diana
ancient
absence
Prior art date
Application number
EC2008008081A
Other languages
English (en)
Spanish (es)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088081A publication Critical patent/ECSP088081A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EC2008008081A 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente ECSP088081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
ECSP088081A true ECSP088081A (es) 2008-02-20

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008081A ECSP088081A (es) 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Country Status (19)

Country Link
US (1) US20070009976A1 (cg-RX-API-DMAC7.html)
EP (2) EP2194380A3 (cg-RX-API-DMAC7.html)
JP (1) JP2008545145A (cg-RX-API-DMAC7.html)
KR (1) KR20080016939A (cg-RX-API-DMAC7.html)
AR (1) AR053948A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006265275A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612591A2 (cg-RX-API-DMAC7.html)
CA (1) CA2613187A1 (cg-RX-API-DMAC7.html)
CR (1) CR9635A (cg-RX-API-DMAC7.html)
EC (1) ECSP088081A (cg-RX-API-DMAC7.html)
IL (1) IL188317A0 (cg-RX-API-DMAC7.html)
MA (1) MA29730B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008000277A (cg-RX-API-DMAC7.html)
MY (1) MY157955A (cg-RX-API-DMAC7.html)
NO (1) NO20076662L (cg-RX-API-DMAC7.html)
NZ (1) NZ564471A (cg-RX-API-DMAC7.html)
RU (1) RU2008103608A (cg-RX-API-DMAC7.html)
TW (1) TWI312864B (cg-RX-API-DMAC7.html)
WO (1) WO2007003420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
US7936392B2 (en) 2004-10-01 2011-05-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PT4403228T (pt) 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
US9815904B2 (en) 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
JP4424987B2 (ja) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
AU2003273218C1 (en) * 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
EP1902315A1 (en) 2008-03-26
CA2613187A1 (en) 2007-01-11
AR053948A1 (es) 2007-05-23
MX2008000277A (es) 2008-03-24
KR20080016939A (ko) 2008-02-22
CR9635A (es) 2008-02-20
MY157955A (en) 2016-08-30
NZ564471A (en) 2010-04-30
US20070009976A1 (en) 2007-01-11
NO20076662L (no) 2008-04-03
AU2006265275A1 (en) 2007-01-11
JP2008545145A (ja) 2008-12-11
MA29730B1 (fr) 2008-09-01
EP2194380A3 (en) 2010-07-14
BRPI0612591A2 (pt) 2010-11-23
EP2194380A2 (en) 2010-06-09
TW200741203A (en) 2007-11-01
WO2007003420A1 (en) 2007-01-11
IL188317A0 (en) 2008-04-13
RU2008103608A (ru) 2009-08-20
TWI312864B (en) 2009-08-01

Similar Documents

Publication Publication Date Title
ECSP088081A (es) Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
EP4249605A3 (en) Methods for analyte detection
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
NZ609824A (en) Immunochromatography devices, methods and kits
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
TW200801202A (en) Alpha-enolase specific antibody and method of use
DE602006011756D1 (de) Komplexformierungs- und -trennungsverfahren
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
MX2009012044A (es) Eliminacion de interferencia en inmunoensayos causada por anticuerpos anti-carbohidrato.
WO2011008831A3 (en) Mass tags for spectrometric analysis of immunoglobulins
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112018017336A2 (pt) método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão
PE20130526A1 (es) Componentes de la pared de celulas de levadura y deteccion de los mismos
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
EA201692071A1 (ru) Иммуноанализ и антитела для обнаружения хромогранина а
EA201691168A1 (ru) Способы исследования бета-глюкана
ES2527703B1 (es) Inmunosensor electroquímico para la determinación cuantitativa de la micotoxina fb1
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
CL2009001907A1 (es) Metodo de deteccion precoz de cancer gastrico que comprende detectar la presencia de marcadores especificos de cancer gastrico en muestras de plasma.
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
WO2018226098A3 (en) METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF
RU2012127077A (ru) Методика проведения иммунохроматографического анализа для серодиагностики